The event is scheduled for 14.00-16.00 on March 26 at: https://financialhearings.com/event/12815
Please register at: https://financialhearings.com/event/12602/register/live_event
Asarina Pharma CEO Peter Nordkild: “Holding the event digitally honors our responsibility to help prevent the spread of Coronavirus, and our responsibility to keep sharing knowledge of PMDD, which remains such a devastating constitution. We warmly invite institutional investors, financial analysts and media.”
The event focuses on the most meaningful clinical effects for a PMDD treatment, and how the company's upcoming Phase IIb data will be evaluated and presented.
The schedule will be approximately as follows:
14.00 – Introduction – Doctor Peter Nordkild: CEO Asarina Pharma.
14.10 – Patient perspective – Paula ‘Fenjima’ Manrique, PMDD patient and advocate, writer, speaker, regular guest as Gaming Expert on Swedish TV4:s Nyhetsmorgon.
14.20 – The PMDD study: 4 key metrics for results – Karin Ekberg, PhD: Chief Operating Officer, Asarina Pharma.
14.40 – The clinical need – Professor Torbjörn Bäckström: Founder and CSO Asarina Pharma, Professor Dept. Clinical Sciences, Obstetrics and Gynecology Umeå University.
14.55 – Experiences from the field – Doctor Paula Briggs: Lead study investigator, Liverpool Woman’s Hospital, consultant in sexual and reproductive health.
15.15 – Q&A